iODN Explorer Set II Endotoxin-free

CHF 650.00
In stock
IAX-300-006-11 SetCHF 650.00
More Information
Product Details
Product Type Set
Application Set Compound Screening
Kit Contains

iODN 2088 (Class I) Endotoxin-free (sterile), 100μg (Cat. No.: IAX-200-050-C100)
iODN (ttaggg)4 (Class II) Endotoxin-free (sterile), 100μg (Cat. No.: IAX-200-051-C100)
iODN G-type-ODN (Class I) Endotoxin-free (sterile), 100μg (Cat. No.: IAX-200-052-C100)
Mini-iODN (Class I) Endotoxin-free (sterile), 100μg (Cat. No.: IAX-200-053-C100)
Mega-iODN (Class I/II) Endotoxin-free (sterile), 100μg (Cat. No.: IAX-200-054-C100)
Duo-iODN (Class I) Endotoxin-free (sterile), 100μg (Cat. No.: IAX-200-055-C100)
Negative control for iODN: Neutral-ODN Endotoxin-free (sterile), 100μg (Cat. No.: IAX-200-202-C100)
ddWater Endotoxin-free (sterile), 10ml (Cat. No.: IAX-900-002-L010)

Other Product Data

Endotoxin free: <0.002EU/μg
Activity: Optimal concentration is dependent upon cell type, species, type and strength of activation and extent of desired inhibition and analysis: in vitro 1-5μM; in vivo 50-300μg in rodent animal models.
Handling: Prepare a 100μM stock solution just prior to use, keep sterile and use only endotoxin-free and sterile ddWater (Cat. No.: IAX-900-002), or PBS (Cat. No.: IAX-900-001).

Click here for Original Manufacturer Product Datasheet: Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by Innaxon.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Avoid freeze/thaw cycles.
After reconstitution, prepare aliquots and keep aqueous stock solutions for 1 day at 4°C or store at -20°C (shelf-life 6 months).
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Manual No
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF

In recent years several groups have studied the sequence requirements, specificity, signalling pathways and kinetics of the TLR (Toll-like receptor) 9 suppression by inhibitory oligonucleotide motifs, which led to a class of novel inhibitory oligonucleotide (iODNs), that is independent of the previously thought species preference. Subsequently it has been discovered that telomeric DNA repeats (TTAGGG)n can block immune activation by CpG-ODNs. Short, 11-15 base long oligonucleotides were synthesized that were capable of potently inhibiting CpG-stimulation. The optimal inhibitory DNA motif consists of a pyrimidine-rich triplet, preferably CCT, which is positioned 5- to the GGG sequence in a singlestranded DNA molecule. Additionally, both the optimal spacing between the CCT and GGG motifs, as well as their relative order to each other, is of crucial importance for the inhibitory DNA action. Interestingly, although both TLR7/TLR8 ligands and bacterial DNA share the endosomal compartment for receptor binding and signal transduction, certain iODNs (G-type) suppress only TLR9-mediated activation, whereas prototype class I iODN may also interfere with the activation via the TLR7/TLR8 pathway. Recently, intriguing evidence has been presented that for some iODN classes the immuno-modulatory biological activity shows only limited sequence dependency or may not even involve TLR-mediated uptake and signaling pathways. For example iODNs of the class II are thought to act on immune activation through inhibition of STAT signalling and independent of TLR signalling via binding to a yet to be identified 'ODN-receptor'. Slightly modified phosphodiester versions of the most potent inhibitory ODNs were also able to profoundly block the immune activation of macrophages and just recently prove to be valuable tools for in vivo use in experimental animal models of inflammatory and auto-immune diseases. Based upon these recent insights the following classification for iODNs has been suggested:

Class I: G-stretch ODNs: TLR9-specific competitors
Class II: ODNs with telomeric repeats: TLR-independent inhibitors of STAT signalling
Class III: Inhibitors of DNA uptake in a sequence independent manner
Class IV: Long phosphorothioate ODNs as direct competitors of TLR9 signalling in a sequence independent manner

Product References
  1. DNA Motifs suppressing TLR9 responses: A. Trieu, et al.; Crit. Rev. Immunol. 26, 527 (2006)
  2. Inhibitory oligodeoxynucleotides-therapeutic promise for systemic autoimmune diseases? P. Lenert; Clin. Exp. Immunol. 140, 1 (2005)
  3. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides: K.J. Ishii, et al.; Curr. Opin. Mol. Ther. 6, 166 (2004)
  4. Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock: H. Shirota, et al.; J. Immunol. 174, 4579 (2005)
  5. Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis: G. Plitas, et al.; J. Exp. Med. 205, 1277 (2008)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.